175 related articles for article (PubMed ID: 23351681)
1. Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: a systematic review.
Bhangu A; Broom L; Nepogodiev D; Gourevitch D; Desai A
Eur J Surg Oncol; 2013 Apr; 39(4):311-9. PubMed ID: 23351681
[TBL] [Abstract][Full Text] [Related]
2. Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients.
Deroose JP; van Geel AN; Burger JW; Eggermont AM; Verhoef C
J Surg Oncol; 2012 May; 105(6):563-9. PubMed ID: 22020863
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
[TBL] [Abstract][Full Text] [Related]
4. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation.
van Ginkel RJ; Thijssens KM; Pras E; van der Graaf WT; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2007 Apr; 14(4):1499-506. PubMed ID: 17253101
[TBL] [Abstract][Full Text] [Related]
5. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
[TBL] [Abstract][Full Text] [Related]
6. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
[TBL] [Abstract][Full Text] [Related]
7. Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study.
Huis In 't Veld EA; Grünhagen DJ; Verhoef C; Smith HG; van Akkooi ACJ; Jones R; van Coevorden F; Hayes AJ; van Houdt WJ
Eur J Cancer; 2017 Nov; 85():114-121. PubMed ID: 28918185
[TBL] [Abstract][Full Text] [Related]
8. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
[TBL] [Abstract][Full Text] [Related]
9. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
[TBL] [Abstract][Full Text] [Related]
10. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
Lejeune FJ; Pujol N; Liénard D; Mosimann F; Raffoul W; Genton A; Guillou L; Landry M; Chassot PG; Chiolero R; Bischof-Delaloye A; Leyvraz S; Mirimanoff RO; Bejkos D; Leyvraz PF
Eur J Surg Oncol; 2000 Nov; 26(7):669-78. PubMed ID: 11078614
[TBL] [Abstract][Full Text] [Related]
11. Treatment modifications in tumour necrosis factor-α (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas.
Deroose JP; Grünhagen DJ; de Wilt JH; Eggermont AM; Verhoef C
Eur J Cancer; 2015 Feb; 51(3):367-73. PubMed ID: 25529370
[TBL] [Abstract][Full Text] [Related]
12. Isolated limb perfusion is an effective treatment modality for locally advanced Kaposi sarcoma of the extremities.
Boere T; Huis In 't Veld EA; Deroose JP; van Ginhoven TM; Wouters MWJM; Grünhagen DJ; Verhoef C; van Houdt WJ
Eur J Surg Oncol; 2020 Jul; 46(7):1315-1319. PubMed ID: 32359920
[TBL] [Abstract][Full Text] [Related]
13. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
[TBL] [Abstract][Full Text] [Related]
14. The oncological outcomes of isolated limb perfusion and neo-adjuvant radiotherapy in soft tissue sarcoma patients - A nationwide multicenter study.
van Praag VM; Fiocco M; Bleckman RF; van Houdt WJ; Haas RLM; Verhoef C; Grunhagen DJ; van Ginkel RJ; Bonenkamp JJ; van de Sande MAJ
Eur J Surg Oncol; 2023 Feb; 49(2):339-344. PubMed ID: 36085118
[TBL] [Abstract][Full Text] [Related]
15. TNF-based isolated limb perfusion in unresectable extremity desmoid tumours.
Grünhagen DJ; de Wilt JH; Verhoef C; van Geel AN; Eggermont AM
Eur J Surg Oncol; 2005 Oct; 31(8):912-6. PubMed ID: 16098709
[TBL] [Abstract][Full Text] [Related]
16. Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma.
Jakob J; Hohenberger P
Cancer; 2016 Sep; 122(17):2624-32. PubMed ID: 27197621
[TBL] [Abstract][Full Text] [Related]
17. The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma.
Grunhagen DJ; de Wilt JH; Graveland WJ; van Geel AN; Eggermont AM
Cancer; 2006 Jan; 106(1):156-62. PubMed ID: 16323177
[TBL] [Abstract][Full Text] [Related]
18. TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long-term patient outcome.
Hoven-Gondrie ML; Bastiaannet E; van Ginkel RJ; Suurmeijer AJ; Hoekstra HJ
J Surg Oncol; 2011 Jun; 103(7):648-55. PubMed ID: 21337343
[TBL] [Abstract][Full Text] [Related]
19. The effect of age on outcomes after isolated limb perfusion for advanced extremity malignancies.
Smith HG; Wilkinson MJ; Smith MJF; Strauss DC; Hayes AJ
Eur J Cancer; 2018 Sep; 100():46-54. PubMed ID: 29940423
[TBL] [Abstract][Full Text] [Related]
20. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation.
Gutman M; Inbar M; Lev-Shlush D; Abu-Abid S; Mozes M; Chaitchik S; Meller I; Klausner JM
Cancer; 1997 Mar; 79(6):1129-37. PubMed ID: 9070490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
